Literature DB >> 33327714

Immunologic characterization of COVID-19 patients with hematological cancer.

Catarina Maia1, Esperanza Martín-Sánchez1, Juan José Garcés1, Ascensión López-Díaz De Cerio2, Susana Inogés2, Manuel F Landecho3, Belén Gil-Alzugaray4, Cristina Perez5, Cirino Botta6, Aintzane Zabaleta1, Félix Alegre3, César Rincón4, Laura Blanco7, Sarai Sarvide5, Amaia Vilas-Zornoza8, Diego Alignani1, Cristina Moreno9, Artur Paiva10, António Martinho11, Rui Alves10, Enrique Colado12, Covadonga Quirós12, Mónica Olid4, Andrés Blanco3, Josepmaria Argemi13, Bruno Paiva1, José Ramón Yuste14.   

Abstract

Not available.

Entities:  

Mesh：

Year:  2020        PMID： 33327714     DOI： 10.3324/haematol.2020.269878

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  7 in total

Review 1.  COVID-19 in Patients with Hematologic Malignancies: Clinical Manifestations, Persistence, and Immune Response.

Authors:  Ivan Gur; Amir Giladi; Yonathan Nachum Isenberg; Ami Neuberger; Anat Stern
Journal:  Acta Haematol       Date:  2022-03-02       Impact factor: 3.068

2.  In-vitro NET-osis induced by COVID-19 sera is associated to severe clinical course in not vaccinated patients and immune-dysregulation in breakthrough infection.

Authors:  Alessandra Romano; Nunziatina Laura Parrinello; Giuseppe Alberto Palumbo; Francesco Di Raimondo; Martina Barchitta; Rosy Manuele; Fabrizio Puglisi; Andrea Maugeri; Alessandro Barbato; Anna Maria Triolo; Cesarina Giallongo; Daniele Tibullo; Lucia La Ferla; Ciro Botta; Sergio Siragusa; Carmelo Iacobello; Arturo Montineri; Giovanni Li Volti; Antonella Agodi
Journal:  Sci Rep       Date:  2022-05-04       Impact factor: 4.996

3.  COVID-19 in patients with hematologic malignancy.

Authors:  Petra Langerbeins; Michael Hallek
Journal:  Blood       Date:  2022-07-21       Impact factor: 25.476

4.  Combined lymphocyte/monocyte count, D-dimer and iron status predict COVID-19 course and outcome in a long-term care facility.

Authors:  Flavia Biamonte; Cirino Botta; Maria Mazzitelli; Salvatore Rotundo; Enrico Maria Trecarichi; Daniela Foti; Carlo Torti; Giuseppe Viglietto; Daniele Torella; Francesco Costanzo
Journal:  J Transl Med       Date:  2021-02-17       Impact factor: 5.531

5.  COVID-19 and CAR T cells: a report on current challenges and future directions from the EPICOVIDEHA survey by EHA-IDWP.

Authors:  Alessandro Busca; Jon Salmanton-García; Paolo Corradini; Francesco Marchesi; Alba Cabirta; Roberta Di Blasi; Remy Dulery; Sylvain Lamure; Francesca Farina; Barbora Weinbergerová; Josip Batinić; Anna Nordlander; Alberto López-García; Ľuboš Drgoňa; Ildefonso Espigado-Tocino; Iker Falces-Romero; Ramón García-Sanz; Carolina García-Vidal; Anna Guidetti; Nina Khanna; Austin Kulasekararaj; Johan Maertens; Martin Hoenigl; Nikolai Klimko; Philipp Koehler; Antonio Pagliuca; Francesco Passamonti; Oliver A Cornely; Livio Pagano
Journal:  Blood Adv       Date:  2022-04-12

6.  Reduced Absolute Count of Monocytes in Patients Carrying Hematological Neoplasms and SARS-CoV2 Infection.

Authors:  Alessandra Romano; Claudio Cerchione; Concetta Conticello; Sabina Filetti; Anna Bulla; Annalisa Chiarenza; Vittorio Del Fabro; Salvatore Leotta; Uros Markovic; Giovanna Motta; Marina Parisi; Fabio Stagno; Giuseppe Alberto Palumbo; Francesco Di Raimondo
Journal:  Cancers (Basel)       Date:  2022-02-24       Impact factor: 6.639

7.  Clobetasol promotes neuromuscular plasticity in mice after motoneuronal loss via sonic hedgehog signaling, immunomodulation and metabolic rebalancing.

Authors:  Nunzio Vicario; Federica M Spitale; Daniele Tibullo; Cesarina Giallongo; Angela M Amorini; Grazia Scandura; Graziana Spoto; Miriam W Saab; Simona D'Aprile; Cristiana Alberghina; Renata Mangione; Joshua D Bernstock; Cirino Botta; Massimo Gulisano; Emanuele Buratti; Giampiero Leanza; Robert Zorec; Michele Vecchio; Michelino Di Rosa; Giovanni Li Volti; Giuseppe Lazzarino; Rosalba Parenti; Rosario Gulino
Journal:  Cell Death Dis       Date:  2021-06-16       Impact factor: 8.469
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.